Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

MOR00208 w/ Idelalisib in Pts w/ Relapsed or Refractory CLL/SLL Previously Treated w/ BTK Inhibitor

Protocol: OSU-16045

Full Title

A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton’s Tyrosine Kinase (BTK) Inhibitor

Chronic Lymphocytic Leukemia Leukemia Lymphoma Non-Hodgkin’s Lymphoma (B- & T-Cell)